Irinotecan and Chemotherapy for Colon Cancer
Author Information
Author(s): Christos A Papadimitriou, Pavlos Papakostas, Maria Karina, Lia Malettou, Meletios A Dimopoulos, George Pentheroudakis, Epaminontas Samantas, Aristotelis Bamias, Dimosthenis Miliaras, George Basdanis, Nikolaos Xiros, George Klouvas, Dimitrios Bafaloukos, Georgia Kafiri, Irene Papaspirou, Dimitrios Pectasides, Charisios Karanikiotis, Theofanis Economopoulos, Ioannis Efstratiou, Ippokratis Korantzis, Nikolaos Pisanidis, Thomas Makatsoris, Fotini Matsiakou, Gerasimos Aravantinos, Haralabos P Kalofonos, George Fountzilas
Primary Institution: Hellenic Cooperative Oncology Group
Hypothesis
Does adding irinotecan to standard chemotherapy improve outcomes for stage II and III colon cancer patients?
Conclusion
Adding irinotecan to standard chemotherapy did not improve survival rates for stage II or III colon cancer but increased toxicity.
Supporting Evidence
- The study included 873 eligible patients.
- Patients were randomly assigned to two treatment arms.
- The probability of overall survival at three years was 0.88 for Arm A and 0.86 for Arm B.
- The probability of disease-free survival at three years was 0.78 for Arm A and 0.76 for Arm B.
- Leucopenia and neutropenia were more common in patients receiving irinotecan.
Takeaway
This study looked at whether adding a drug called irinotecan to standard treatment helps people with colon cancer live longer. It found that it doesn't help but can make people feel worse.
Methodology
Patients were randomly assigned to receive either irinotecan with leucovorin and 5FU or leucovorin and 5FU alone, with a total of 873 patients included in the study.
Limitations
The study did not find significant differences in survival rates, and the addition of irinotecan increased toxicity.
Participant Demographics
Patients had histologically confirmed colon adenocarcinoma and were aged at least 18 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website